TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 28617962

Group type: EXPERIMENTAL
Intervention: Supportive discourse with affirmative and negative sentences
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Blocked presentation of affirmative and negative sentences (affirmatives first)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Randomized sentence types
Number of subjects: 44
Study: 27473777

Group type: EXPERIMENTAL
Intervention: Postoperative wound complications (WCs)
Number of subjects: 500

Group type: COMPARATOR
Intervention: No complication (NC)
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Claudication subgroup
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Rest pain and tissue loss groups
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Abdominal aortic aneurysm cohort
Number of subjects: 500
Study: 24531203

Group type: EXPERIMENTAL
Intervention: Higher-Intensity Interval Training (HIIT)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Moderate-Intensity Continuous Training (MCT)
Number of subjects: 39
Study: 23067923

Group type: EXPERIMENTAL
Intervention: Web-based self-management program with home blood pressure cuff
Number of subjects: 404

Group type: COMPARATOR
Intervention: Onsite blood pressure cuff (Control)
Number of subjects: 404
Study: 20136766

Group type: EXPERIMENTAL
Intervention: Football training program
Number of subjects: 22

Group type: COMPARATOR
Intervention: Standard exercise program
Number of subjects: 22
Study: 18981463

Group type: EXPERIMENTAL
Intervention: ABT-510 20 mg once a day
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: ABT-510 100 mg twice a day
Number of subjects: 88
Study: 15653656

Group type: EXPERIMENTAL
Intervention: (90)Y-DOTATOC
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: (177)Lu-DOTATATE
Number of subjects: 65
Study: 12207594

Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IVIG) 2 g kg‐1, administered as an 8‐h infusion of 1 g kg‐1 daily for two consecutive days
Number of subjects: 10

Group type: COMPARATOR
Intervention: Delayed treatment with IVIG (control group)
Number of subjects: 10
Study: 10587392

Group type: EXPERIMENTAL
Intervention: Dacron bypass graft
Number of subjects: 419

Group type: COMPARATOR
Intervention: Polytetrafluoroethylene bypass graft
Number of subjects: 419
Study: 8903550

Group type: EXPERIMENTAL
Intervention: Burch colposuspension
Number of subjects: 51

Group type: COMPARATOR
Intervention: Stamey endoscopic bladder neck suspension
Number of subjects: 51
Study: 1758315

Group type: EXPERIMENTAL
Intervention: Computer-assisted instruction (CAI)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Combination of seminar teaching and audiotapes
Number of subjects: 35

Group type: COMPARATOR
Intervention: Seminar teaching plus audiotapes
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Combination of CAI and seminar teaching
Number of subjects: 35
Study: 31894026

Group type: EXPERIMENTAL
Intervention: Pemetrexed combined with platinum drugs and evidence‐based nursing mode
Number of subjects: 200

Group type: COMPARATOR
Intervention: Pemetrexed therapy and routine nursing mode
Number of subjects: 200
Study: 28271312

Group type: EXPERIMENTAL
Intervention: Cycling with superimposed EMS (C + E)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Cycling (C)
Number of subjects: 21
Study: 25935433

Group type: EXPERIMENTAL
Intervention: 30 minutes of moderate-intensity exercise on a treadmill
Number of subjects: 14

Group type: COMPARATOR
Intervention: 30 minutes of rest
Number of subjects: 14
Study: 23665341

Group type: EXPERIMENTAL
Intervention: Adjuvanted vaccines (30 μg, 60 μg, 90 μg)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: 30 μg adjuvanted formulation
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: All doses and formulations
Number of subjects: 300

Group type: COMPARATOR
Intervention: Non-adjuvanted vaccines (30 μg, 60 μg, 90 μg)
Number of subjects: 300
Study: 21430645

Group type: EXPERIMENTAL
Intervention: Pregabalin 50 mg
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Pregabalin 200 mg
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 19225432

Group type: EXPERIMENTAL
Intervention: Clear sunglasses
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Gray sunglasses
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Green sunglasses
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Yellow-green sunglasses
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Yellow-brown sunglasses
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Red-brown sunglasses
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Green tint
Number of subjects: 69
Study: 17723807

Group type: EXPERIMENTAL
Intervention: Head-down tilt group (n = 17)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control group (n = 17)
Number of subjects: 34
Study: 15151685

Group type: EXPERIMENTAL
Intervention: Toothpaste containing 1450 ppm F
Number of subjects: 3467

Group type: EXPERIMENTAL
Intervention: Toothpaste containing 440 ppm F
Number of subjects: 3467

Group type: COMPARATOR
Intervention: Comparison group (no intervention)
Number of subjects: 3467

Group type: EXPERIMENTAL
Intervention: Both low- and high-fluoride toothpaste
Number of subjects: 3467
Study: 11794040

Group type: EXPERIMENTAL
Intervention: HRT (oestrogen)
Number of subjects: 2016

Group type: COMPARATOR
Intervention: No HRT
Number of subjects: 2016
Study: 9868662

Group type: EXPERIMENTAL
Intervention: Ceftriaxone 2 g once daily for 4 weeks
Number of subjects: 61

Group type: COMPARATOR
Intervention: Ceftriaxone 2 g plus gentamicin 3 mg/kg once daily for 2 weeks
Number of subjects: 61
Study: 8027914

Group type: EXPERIMENTAL
Intervention: Residential treatment for 2 years
Number of subjects: 50
Study: 2528705

Group type: EXPERIMENTAL
Intervention: Diethylstilboestrol (DES)
Number of subjects: 92
Study: 791194

Group type: EXPERIMENTAL
Intervention: 150 mg maprotiline per day
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 225 mg maprotiline per day
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 300 mg maprotiline per day (initial dosage for first 2 days)
Number of subjects: 20
Study: 30377712

Group type: EXPERIMENTAL
Intervention: L-arginine (9 g/day) for 6 weeks
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Skeletal muscle biopsies
Number of subjects: 20
Study: 28292574

Group type: EXPERIMENTAL
Intervention: Lipid-containing lubricant eye drop (Systane® Balance)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Phospholipid liposomal spray (Tears Again®)
Number of subjects: 50
Study: 26188837

Group type: EXPERIMENTAL
Intervention: Oral solution of apixaban 10 mg
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Oral solution via NGT flushed with D5W
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Oral solution via NGT flushed with infant formula
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Oral solution via NGT with nutritional supplement
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Crushed tablet suspended in D5W via NGT
Number of subjects: 3

Group type: COMPARATOR
Intervention: Oral solution of apixaban 5 mg
Number of subjects: 3

Group type: COMPARATOR
Intervention: Crushed tablet via NGT
Number of subjects: 3
Study: 23252829

Group type: EXPERIMENTAL
Intervention: Tangible reward (sticker)
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Verbal reward (praise)
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: No reward
Number of subjects: 137

Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 137
Study: 21228739

Group type: EXPERIMENTAL
Intervention: Skin stretching device for wound closure
Number of subjects: 30

Group type: COMPARATOR
Intervention: Scar excision without additional techniques (control)
Number of subjects: 30
Study: 18309164

Group type: EXPERIMENTAL
Intervention: Prophylactic mezlocillin plus sulbactam (3 x 2 g/1 g for 4 days)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional management
Number of subjects: 60
Study: 16877734

Group type: EXPERIMENTAL
Intervention: Docetaxel 60 mg/m2 (day 1) every 21 days for four cycles
Number of subjects: 182

Group type: COMPARATOR
Intervention: Vinorelbine 25 mg/m2 (days 1 and 8) every 21 days for four cycles
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: Docetaxel
Number of subjects: 182

Group type: COMPARATOR
Intervention: Vinorelbine
Number of subjects: 182
Study: 12917503

Group type: EXPERIMENTAL
Intervention: High-CHO diet (58% of energy as carbohydrates)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: High-MUFA diet (40% of energy as fat, 23% as MUFAs)
Number of subjects: 63
Study: 11194957

Group type: EXPERIMENTAL
Intervention: Locoregional irradiation after mastectomy
Number of subjects: 7840

Group type: EXPERIMENTAL
Intervention: Modern radiotherapy
Number of subjects: 7840
Study: 9013263

Group type: EXPERIMENTAL
Intervention: Vitamin E 400 mg once a day orally for 4 weeks
Number of subjects: 20

Group type: COMPARATOR
Intervention: Pre-treatment state
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Heart failure patients with ejection fraction < 40%
Number of subjects: 20
Study: 1394580

Group type: EXPERIMENTAL
Intervention: Aerosolized pilocarpine
Number of subjects: 25

Group type: COMPARATOR
Intervention: Histamine alone
Number of subjects: 25
Study: 3890159

Group type: EXPERIMENTAL
Intervention: Steroid injections
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 29759061

Group type: EXPERIMENTAL
Intervention: TAP block with 20 ml 0.375% ropivacaine
Number of subjects: 139
Study: 27449358

Group type: COMPARATOR
Intervention: Comprehensive (Family Healthy Lifestyle plus Family Recreation programs)
Number of subjects: 1168

Group type: COMPARATOR
Intervention: Family Healthy Lifestyle
Number of subjects: 1168

Group type: COMPARATOR
Intervention: Family Recreation
Number of subjects: 1168

Group type: COMPARATOR
Intervention: Self-Directed (no intervention)
Number of subjects: 1168
Study: 24708394

Group type: EXPERIMENTAL
Intervention: Small graft group (FGG thickness <2 mm, height 4 mm)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Big graft group (FGG thickness ≥ 2 mm, height equal to bone dehiscence)
Number of subjects: 60
Study: 22230323

Group type: EXPERIMENTAL
Intervention: Rosuvastatin 20 mg/d
Number of subjects: 6766

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6766

Group type: EXPERIMENTAL
Intervention: Rosuvastatin (genetic association)
Number of subjects: 6766

Group type: COMPARATOR
Intervention: Placebo (genetic association)
Number of subjects: 6766
Study: 20723849

Group type: EXPERIMENTAL
Intervention: Bivalirudin
Number of subjects: 2530

Group type: COMPARATOR
Intervention: UFH plus GPI
Number of subjects: 2530
Study: 19006764

Group type: EXPERIMENTAL
Intervention: Maximal abduction (32.6N)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Maximal adduction (42.4N)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Multifinger performance
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Coordination of AbAd
Number of subjects: 21
Study: 16192478

Group type: EXPERIMENTAL
Intervention: DrotAA (24 microg/kg/hour for 96 hours)
Number of subjects: 2613

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2613
Study: 14675884

Group type: EXPERIMENTAL
Intervention: Simvastatin (20 mg/day) + ACE inhibitor (lisinopril 5 mg/day)
Number of subjects: 56

Group type: COMPARATOR
Intervention: ACE inhibitor (lisinopril 5 mg/day) alone
Number of subjects: 56
Study: 10982926

Group type: EXPERIMENTAL
Intervention: Bioefficient Therapy
Number of subjects: 90

Group type: COMPARATOR
Intervention: simplified standard edgewise technique
Number of subjects: 90

Group type: COMPARATOR
Intervention: edgewise straight wire system
Number of subjects: 90
Study: 8971373

Group type: EXPERIMENTAL
Intervention: GM‐CSF (10 micrograms/kg/day)
Number of subjects: 403

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 403
Study: 1294745

Group type: EXPERIMENTAL
Intervention: Acetaminophen
Number of subjects: 182

Group type: COMPARATOR
Intervention: Ibuprofen (analgesic and antiinflammatory doses)
Number of subjects: 182
Study: 4007361

Group type: EXPERIMENTAL
Intervention: M-mode echocardiography
Number of subjects: 36
Study: 30322875

Group type: EXPERIMENTAL
Intervention: Screened twice or three times
Number of subjects: 31867

Group type: COMPARATOR
Intervention: Screened once
Number of subjects: 31867

Group type: COMPARATOR
Intervention: Control arm
Number of subjects: 31867

Group type: EXPERIMENTAL
Intervention: Screened three times
Number of subjects: 31867
Study: 28130574

Group type: EXPERIMENTAL
Intervention: PDUS-guided core-needle biopsy (CNCB)
Number of subjects: 372

Group type: COMPARATOR
Intervention: Standard surgical biopsy (OSB)
Number of subjects: 372
Study: 26192721

Group type: EXPERIMENTAL
Intervention: ACDF followed by physiotherapy
Number of subjects: 60

Group type: COMPARATOR
Intervention: Physiotherapy alone
Number of subjects: 60
Study: 23220919

Group type: EXPERIMENTAL
Intervention: 900 mg INH twice weekly for 6 months
Number of subjects: 0

Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 0
Study: 21612950

Group type: EXPERIMENTAL
Intervention: Part-task rehearsal (PTr)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Full-task rehearsal (FTr)
Number of subjects: 20
Study: 19531640

Group type: COMPARATOR
Intervention: Hypocaloric diet and aerobic exercise (1 h/day at 65% of maximal oxygen uptake)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Eucaloric diet and aerobic exercise (1 h/day at 65% of maximal oxygen uptake)
Number of subjects: 16
Study: 16783518

Group type: EXPERIMENTAL
Intervention: Remote Associations Task
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Verbal word-generation and simple association tasks
Number of subjects: 39
Study: 15504190

Group type: EXPERIMENTAL
Intervention: Dixyrazine 10 mg
Number of subjects: 197

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 197
Study: 11526982

Group type: EXPERIMENTAL
Intervention: 4-aminopyridine (10 mg capsule)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 9760006

Group type: EXPERIMENTAL
Intervention: Policosanol 5 mg twice daily
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Policosanol 5 mg twice daily plus 125 mg aspirin
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo plus 125 mg aspirin
Number of subjects: 45
Study: 7919892

Group type: EXPERIMENTAL
Intervention: Endoscopic ultrasonographic examinations (EUS)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Liposomal encapsulated Doxorubicin (20 mg/m2 intravenously every 3 weeks)
Number of subjects: 22
Study: 2455155

Group type: EXPERIMENTAL
Intervention: Metoprolol (MET), 200 mg slow release (SR) q.d.
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Nifedipine (NIF), 20 mg SR b.i.d.
Number of subjects: 20

Group type: COMPARATOR
Intervention: Metoprolol (MET)
Number of subjects: 20
Study: 31628477

Group type: EXPERIMENTAL
Intervention: Exercise performed before breakfast
Number of subjects: 2

Group type: COMPARATOR
Intervention: Exercise performed after breakfast
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Exercise training performed before carbohydrate intake
Number of subjects: 2

Group type: COMPARATOR
Intervention: Exercise training performed after carbohydrate intake
Number of subjects: 2
Study: 29939254

Group type: EXPERIMENTAL
Intervention: Adalimumab
Number of subjects: 36
Study: 28679410

Group type: EXPERIMENTAL
Intervention: Moxibustion treatment at CV8, CV12, LI4 and ST36, 30-min treatments twice a week for 8 weeks
Number of subjects: 96

Group type: COMPARATOR
Intervention: Sham moxibustion at non-acupoints, 30-min treatments twice a week for 8 weeks
Number of subjects: 96

Group type: COMPARATOR
Intervention: Usual care group (no moxibustion treatment)
Number of subjects: 96
Study: 26235788

Group type: EXPERIMENTAL
Intervention: Corrective strabismus surgery (n = 63)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Active monitoring without surgery (n = 57)
Number of subjects: 130
Study: 22486205

Group type: EXPERIMENTAL
Intervention: 30 mg pioglitazone
Number of subjects: 20
Study: 21635753

Group type: EXPERIMENTAL
Intervention: Staircase recruitment manoeuvres (SRM) with decremental PEEP titration and targeted plateau pressure < 30 cm H2O
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control ventilation strategies (ARDSnet)
Number of subjects: 20
Study: 19783515

Group type: EXPERIMENTAL
Intervention: Powdered cherry stalk (2.0 grams per person)
Number of subjects: 13
Study: 17050481

Group type: EXPERIMENTAL
Intervention: Extensive mobile phone users
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 21
Study: 12757064

Group type: EXPERIMENTAL
Intervention: Ginger (2 capsules of 0.5 g ginger powder each, taken 1 hour before the procedure)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 80
Study: 10702769

Group type: EXPERIMENTAL
Intervention: Orlistat (120 mg three times/day)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 10096413

Group type: EXPERIMENTAL
Intervention: Overt word reading tasks
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Overt nonword reading tasks
Number of subjects: 10
Study: 7901254

Group type: EXPERIMENTAL
Intervention: Aspirin alone
Number of subjects: 358

Group type: EXPERIMENTAL
Intervention: Aspirin plus heparin followed by aspirin plus warfarin
Number of subjects: 358
Study: 2449725

Group type: EXPERIMENTAL
Intervention: Transurethral incision
Number of subjects: 37

Group type: COMPARATOR
Intervention: Transurethral resection
Number of subjects: 37
Study: 29940417

Group type: EXPERIMENTAL
Intervention: Atosiban as uterine relaxant
Number of subjects: 818

Group type: COMPARATOR
Intervention: Fenoterol as uterine relaxant
Number of subjects: 818
Study: 26598955

Group type: EXPERIMENTAL
Intervention: Self-collected HPV testing kit
Number of subjects: 818

Group type: COMPARATOR
Intervention: Reminder invitation for Pap testing
Number of subjects: 818

Group type: COMPARATOR
Intervention: Standard of care opportunistic screening
Number of subjects: 818
Study: 24056065

Group type: EXPERIMENTAL
Intervention: Work-related rehabilitation programme following a comprehensive functional capacity evaluation (FCE MR)
Number of subjects: 222

Group type: COMPARATOR
Intervention: Conventional multidisciplinary rehabilitation (C)
Number of subjects: 222
Study: 21930514

Group type: EXPERIMENTAL
Intervention: In-shoe foot orthoses
Number of subjects: 40

Group type: COMPARATOR
Intervention: Wait-and-see policy
Number of subjects: 40
Study: 20963310

Group type: EXPERIMENTAL
Intervention: Ministernotomy (MS)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Conventional Midsternotomy (CMS)
Number of subjects: 18
Study: 19076083

Group type: COMPARATOR
Intervention: Angiotensin-converting enzyme inhibitors (ACE-Is) introduced 3-16 days after MI
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 16550960

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy
Number of subjects: 0
Study: 14572753

Group type: EXPERIMENTAL
Intervention: Permixon (160 mg bid for three months)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Permixon
Number of subjects: 29

Group type: COMPARATOR
Intervention: Control (no treatment for 3 weeks before surgery)
Number of subjects: 29
Study: 10962896

Group type: EXPERIMENTAL
Intervention: Subtotal colectomy for obstructive left side colonic tumours
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Total mesorectal excision for middle and lower third rectal cancer
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Multivisceral resections for the treatment of advanced colorectal tumours
Number of subjects: 0
Study: 9380919

Group type: EXPERIMENTAL
Intervention: 10 mg of propofol administered i.v. immediately after fetal extraction
Number of subjects: 60

Group type: COMPARATOR
Intervention: Intralipid (equal volume to propofol)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Top-up antiemetic drug (dehydro-benzoperidol)
Number of subjects: 60
Study: 8411145

Group type: EXPERIMENTAL
Intervention: Fish oil (2.4 g long‐chain n‐3 fatty acids/day) for 4 weeks
Number of subjects: 20

Group type: COMPARATOR
Intervention: Olive oil
Number of subjects: 20
Study: 3964152

Group type: EXPERIMENTAL
Intervention: Transdermal scopolamine
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 31629656

Group type: EXPERIMENTAL
Intervention: Radiotherapy plus goserelin (10.8 mg subcutaneous injection on the first day of irradiation and 3 months later)
Number of subjects: 743

Group type: COMPARATOR
Intervention: Radiotherapy alone
Number of subjects: 743
Study: 26905082

Group type: EXPERIMENTAL
Intervention: Gait plate insole with shoes
Number of subjects: 17

Group type: COMPARATOR
Intervention: Shoes only
Number of subjects: 17
Study: 25347023

Group type: EXPERIMENTAL
Intervention: Prequit smoking-specific experiential avoidance (EA)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Prequit smoking-specific EA
Number of subjects: 40
Study: 23883408

Group type: EXPERIMENTAL
Intervention: Predictive low-glucose suspend (PLGS) system active
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control (PLGS system inactive)
Number of subjects: 19
Study: 21977566

Group type: EXPERIMENTAL
Intervention: Vaginal birth after caesarean section (VBAC)
Number of subjects: 357

Group type: EXPERIMENTAL
Intervention: Duration of first stage of labour
Number of subjects: 357

Group type: EXPERIMENTAL
Intervention: Duration of second stage of labour
Number of subjects: 357

Group type: COMPARATOR
Intervention: Control group (women without previous caesarean section)
Number of subjects: 357

Group type: EXPERIMENTAL
Intervention: Complications of VBAC
Number of subjects: 357
Study: 19387560

Group type: EXPERIMENTAL
Intervention: Curriculum for rotation physicians within the CHIR-Net
Number of subjects: 0
Study: 16954475

Group type: EXPERIMENTAL
Intervention: LHA intervention group
Number of subjects: 851

Group type: COMPARATOR
Intervention: Comparison group
Number of subjects: 851
Study: 15312156

Group type: EXPERIMENTAL
Intervention: Amlodipine 5-10 mg
Number of subjects: 246

Group type: COMPARATOR
Intervention: Valsartan 40-80 mg
Number of subjects: 246
Study: 11745199

Group type: EXPERIMENTAL
Intervention: Paclitaxel (135 mg/m2) over 24 hours with cisplatin (75 mg/m2) on a 21‐day cycle
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Cisplatin (100 mg/m2) with gemcitabine (1 g/m2) on Days 1, 8, and 15 on a 28‐day cycle
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Cisplatin (75 mg/m2) with docetaxel (75 mg/m2) on a 21‐day cycle
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Paclitaxel (225 mg/m2) over 3 hours with carboplatin (area under the curve, 6)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Overall treatment
Number of subjects: 68

Group type: COMPARATOR
Intervention: Comparison with patients with PS of 0-1
Number of subjects: 68